Reaction of DDAbs From Chimpanzee A-264, Rhesus Monkey 94-R021, and Control Chimpanzee Plasma With Platelets From a Glanzmann’s Thrombasthenic Patient and a Control Human Subject
| Platelets . | Plasma . | ||
|---|---|---|---|
| Chimpanzee A-264 . | Rhesus 94-R021 . | Control Chimpanzee . | |
| Glanzmann’s patient | |||
| A1-L | 1.2 | 1.0 | 1.0 |
| A2-L | 1.1 | 1.1 | 1.0 |
| B | 1.1 | 1.2 | 1.1 |
| Control human subject | |||
| A1-L | 2.3 | 1.1 | 1.1 |
| A2-L | 5.2 | 1.0 | 1.2 |
| B | 1.2 | 3.3 | 1.0 |
| Platelets . | Plasma . | ||
|---|---|---|---|
| Chimpanzee A-264 . | Rhesus 94-R021 . | Control Chimpanzee . | |
| Glanzmann’s patient | |||
| A1-L | 1.2 | 1.0 | 1.0 |
| A2-L | 1.1 | 1.1 | 1.0 |
| B | 1.1 | 1.2 | 1.1 |
| Control human subject | |||
| A1-L | 2.3 | 1.1 | 1.1 |
| A2-L | 5.2 | 1.0 | 1.2 |
| B | 1.2 | 3.3 | 1.0 |
The reaction of DDAbs expressed as relative fluorescence (fluorescence in the presence of the drug/fluorescence in the absence of the drug) obtained in the flow cytometric assay (for details, see Materials and Methods). Values ≥2 are considered a positive indication of DDAb binding. Values of relative fluorescence represent an average of two independent measurements.